CD59 and Burkitt lymphoma: In addition, these results revealed a difference between the IPI-145 and midostaurin effects on regulating CD20 and CD59 expression, in which IPI-145 only reduced CD20 but not CD59 expression in the resistant BL cells (Fig. 2a).